Publicaciones en colaboración con investigadores/as de University of Cincinnati (9)

2024

  1. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  2. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, Vol. 34, Núm. 7, pp. 1041-1050

  3. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

    European Journal of Cancer, Vol. 208

2023

  1. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

    International Journal of Gynecological Cancer, Vol. 33, Núm. 11, pp. 1733-1742

  2. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

    Gynecologic Oncology, Vol. 170, pp. 300-308

  3. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570

2021

  1. Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

    Oral Oncology, Vol. 115

2019

  1. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    International Journal of Gynecological Cancer, Vol. 29, Núm. 7, pp. 1094-1097

  2. Joint ENGOT and GOG Foundation requirements for trials with industry partners

    Gynecologic Oncology